Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752.

Authors :: Chung, Vincent
Guthrie, Katherine A.
Pishvaian, Michael J.
Lowy, Andrew M.
Sohal, Davendra
Reiss, Kim Anna
Sanford, Nina Niu
Allegra, Carmen
Colby, Sarah
O'Reilly, Eileen M.
Chiorean, E. Gabriela
Philip, Philip Agop
Source :: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, pTPS793-TPS793, 121p
Publication Year :: 2025

Full Text Access

Tools